12 results about "Cellular lipid" patented technology

This invention belongs to the field of biomedical technology, specifically relating to a compound extracted from *Acer buergerianum* (a type of shrub), its extraction method, and its application in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease. This invention is the first to obtain a natural compound with a novel structure from *Acer buergerianum*, and provides a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity and no significant cytotoxicity to normal cells. It can inhibit the expression of fatty acid synthases ACC, ACLY, and FAS, thereby inhibiting de novo fatty acid synthesis in cells, suppressing lipid droplet accumulation, and reducing cellular lipid levels. This compound has broad application prospects in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease.

This invention relates to a compound extracted from *Dryopteris macrocarpa*, its extraction method, and its application in the preparation of drugs for the prevention and / or treatment of non-alcoholic fatty liver disease. This invention provides a novel natural compound obtained from *Dryopteris macrocarpa* for the first time, along with a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity to normal cells. It can inhibit fatty acid uptake in cells by suppressing the expression of fatty acid uptake-related genes FATP2 and CD36, thereby inhibiting lipid droplet accumulation and reducing cellular lipid levels. This compound can be applied in the preparation of drugs for the prevention and / or treatment of non-alcoholic fatty liver disease.

This invention discloses refined mulberry seed oil, its extraction method, and its application. Compared with the prior art, the advantages are: (1) The method of this invention uses agricultural waste (mulberry seeds) as raw material, and obtains mulberry seed oil through low-moisture enzymatic hydrolysis pretreatment combined with high-temperature pressing. The enzyme dosage is low (0.1%~1.0%), ethanol is recycled, solvent loss is small, the process is simple, the operation is convenient, and it is easy to realize industrial-scale production; (2) The mulberry seed oil prepared by this invention has an unsaturated fatty acid content of up to 88.26%, of which the linoleic acid content is 81.6%; (3) The mulberry seed oil of this invention shows significant lipid-regulating activity in both cell and nematode models: it can improve the lipid content index and protein expression of hyperlipidemic cells, and it can also regulate nematode-related genes and reduce lipid accumulation; (4) This invention uses mulberry seeds, a waste of silkworms, as raw material, and realizes the high-value utilization of agricultural by-products, which has good industrial application prospects and economic and social benefits.

The present application relates to the technical field of compounds, in particular to a natural active compound pseudo-norfurane, a preparation method and application thereof. The present application provides a natural active compound pseudo-norfurane, which has the structure shown in the following formula (I), the compound formula (I) of the present application can significantly reduce the lipid accumulation in a HepG2 cell lipid model, has a hypolipidemic biological activity, can be used for preparing a hypolipidemic drug or a hypolipidemic health food, and has a good development and application prospect.

The invention discloses a construction method of a hepatocyte lipid accumulation model and application of the hepatocyte lipid accumulation model in screening of lipid-lowering functional substances, and belongs to the technical field of detection. The method comprises the following steps: culturing AML12 cells by using a DMEM / F-12 culture medium containing 10% of FBS, 1 * ITS and 1% of P / S, carrying out combined intervention for 24-72 hours by using 2%-3% of ethanol and 50-100 [mu] M of palmitic acid for molding, and quantifying the intracellular lipid accumulation degree through BODIPY fluorescence detection. The model simulates pathological mechanisms of alcoholism and high fat diet, AML12 cells retain key enzymes of alcohol metabolism, the cell viability is maintained at 60%-80% after modeling, and the lipid fluorescence intensity is remarkably improved compared with that of a blank group. The model can efficiently screen lipid-lowering and liver-protecting functional substances for relieving alcoholic fatty liver, is sensitive and quantifiable in detection, and provides a reliable tool for screening related medicines and extracts.

Polynucleotides such as DNA are stored inside vesicles formed from self-assembling membranes. The vesicles may be protocells, liposomes, micelles, colloidosomes, proteinosomes, or coacervates. The vesicles may include surface functionalization to improve polynucleotide encapsulation and / or to bind polynucleotides having specific sequences. Encapsulation in vesicles provides protection for the polynucleotides. Additional protection is provided by addition of one or more stabilizers. The stabilizer may be nucleic-acid stabilizers that stabilize the polynucleotides or may be a protective structural layer around the vesicles such as a layer of silica. A process for stably storing polynucleotides in vesicles and a process for recovering stored polynucleotides from vesicles are both disclosed. The polynucleotides may be used for storage of digital information.

The application discloses the use of ACY-1 modulators as a therapeutic target for fatty liver disease and drug screening. By constructing a HepG2 cell lipid deposition model, it is found for the first time that ACY1 overexpression can exacerbate cell triglyceride accumulation; by constructing a MASH mouse model induced by a high-fat high-cholesterol high-fructose diet, it is found that ACY1 overexpression can exacerbate MASH progression; based on these findings, a drug screening method for preventing or treating fatty liver disease is constructed, and 2-hydroxyhexanoic acid (2-HHA) is screened out, which can significantly inhibit the in vitro enzyme activity of ACY1, and can alleviate abnormal cell triglyceride accumulation caused by palmitic acid-oleic acid stimulation at the cell and animal levels, and significantly improve the weight gain, liver lipid deposition, fatty degeneration, inflammatory infiltration and fibrosis of MASH mice induced by a high-fat high-cholesterol high-fructose diet, and the like, in addition, the inhibitor 2-hydroxyhexanoic acid can significantly reduce the abnormally increased serum ALT, AST and liver TC and TG of MASH mice.

The application discloses a traditional Chinese medicine polysaccharide with lipid-lowering activity and a preparation method and application thereof, relates to the technical field of biological medicine, and the traditional Chinese medicine polysaccharide is neutral uniform polysaccharide ACP1 in allium chinense, the weight-average molecular weight is 17.96 kDa, the polydispersity index is 1.726, is composed of glucose and fructose, and the molar ratio is 2.53%:97.47%. The neutral uniform polysaccharide in allium chinense provided in the application is a new neutral uniform polysaccharide ACP1 extracted from allium chinense, can effectively improve the lipid deposition of AML-12 cells induced by oleic acid, has significant lipid-lowering activity, and is high in safety. The preparation method of the neutral uniform polysaccharide in allium chinense provided in the application is good in repeatability, the obtained neutral uniform polysaccharide is high in purity, and is beneficial to industrial production.

The invention provides a method and a device for screening membrane proteins. The device comprises a first fusion protein comprising a membrane protein present in a boundary layer (e.g., the wall of a cell, liposome, or vesicle) and fused to one member of a binding pair, and a second fusion protein comprising an intracellular ligand fused to the membrane protein of the other member of the binding pair, wherein the combination pair is capable of generating a detectable signal.

This invention discloses a method for extracting lipid components from dermal adipocytes and its application, comprising the following steps: (1) extracting primary dermal fibroblasts from mice on day 0 of birth; (2) culturing the primary dermal fibroblasts in DMEM+++ medium until the cell adhesion density reaches 100%, then inducing adipogenic differentiation in vitro using adipogenic differentiation medium, and then maintaining the culture in maintenance medium until the cells are in an early adipogenic state, and separating the supernatant of the early differentiated cells; (3) extracting and separating the supernatant obtained in step (2) using the Matyash method to obtain the lipid components of the dermal adipocytes. This invention, by extracting and separating lipid and protein components from the supernatant of early differentiated adipocyte culture, obtains lipid components with significant immunomodulatory functions, which can significantly inhibit the inflammatory state of macrophages and the proliferation of keratinocytes.

The invention relates to a gene target spot and a medicine for treating glycolipid metabolism related diseases, and belongs to the technical field of biological medicines. The invention provides application of an ARPP21 gene and / or protein as a target spot in preparation of drugs for preventing and / or treating diseases related to glycolipid metabolism. The invention finds that the weight of an ARPP21 knockout mouse becomes lighter, visceral organs are injured, and compared with a wild mouse, the liver has fat deposition and lipid metabolism related factor expression is up-regulated. According to the present invention, by constructing the AML-12 cell capable of overexpressing and knocking down the Arpp21, the expression of the lipid metabolism related gene of the AML-12 cell capable of knocking down the ARPP21 is increased, and after the cell lipid deposition is induced, the adiposis of the AML-12 cell capable of overexpressing the Arpp21 is reduced; according to the invention, the function and mechanism of the ARPP21 participating in glycolipid metabolism pathways in the liver and muscles are defined, and a new therapeutic target and strategy are provided for glycolipid metabolic diseases.

The invention belongs to the technical field of biological medicines, particularly relates to application of PLIN3 in preparation of a medicine for improving or inhibiting foaming of vascular smooth muscle cells, and provides a new strategy for improving foaming of the vascular smooth muscle cells. Vascular smooth muscle cell foaming is a key process of atherosclerosis development. The exploration process of the PLIN3 for improving vascular smooth muscle cell foaming comprises the following steps: 1) constructing a foamed cell model; 2) screening and determining treatment targets; and 3) the specific effect of the PLIN3 in regulating and controlling the lipid homeostasis of the vascular smooth muscle cells. Researches find that the knock-down of the PLIN3 can effectively reduce lipid accumulation of vascular smooth muscle cells, the over-expression of the PLIN3 obviously promotes intracellular lipid accumulation, and the PLIN3 plays an important role in maintaining a cell lipid steady state. Therefore, the medicine targeting the PLIN3 has application potential in the aspect of preventing and treating the atherosclerosis and other lipid metabolism syndromes.